The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors

Molecular Cancer Research

Volumn 7, Issue 10, 2009, Pages 1736-1743

  Rho, Jin Kyung ^a,b   Choi, Yun Jung ^a   Lee, Jin Kyung ^a   Ryoo, Baek Yeol ^a   Na, Im Il ^a   Yang, Sung Hyun ^a   Lee, Seung Sook ^a   Kim, Cheol Hyeon ^a   Yoo, Young Do ^b   Lee, Jae Cheol ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; SCATTER FACTOR;

ARTICLE; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; DRUG SENSITIVITY; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 72449198117     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0504     Document Type: Article

References (33)

1. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006;12:7117-7125 (Pubitemid 44974512)
2. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144 (Pubitemid 41058345)
3. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247 (Pubitemid 41103678)
4. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
5. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769 (Pubitemid 44629607)
6. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043
7. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300. (Pubitemid 37328782)
8. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-417 (Pubitemid 36119916)
9. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-met tyrosine kinase. Trends Cell Biol 1998;8:404-410 (Pubitemid 28458706)
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat RevMol Cell Biol 2003;4:915-925
11. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in nonsmall- cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008.
12. Yun CH, Menqwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075
13. Rubin H. Cell aging in vivo and in vitro. Mech Ageing Dev 1997;98:1-35.
14. Mamaeva SE. The patterns of the karyotypic evolution of cells in culture. Tsitologiia 1996;38:787-814.
15. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Crosstalk between epidermal growth factor receptor and c-met signal pathways in transformed cells. J Biol Chem 2000;275:8806-8811 (Pubitemid 30180235)
16. Xu KP, Yu FS. Cross talk between c-met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest Ophthalmol Vis Sci 2007;48:2242-2248 (Pubitemid 351261301)
17. Oqino A, Kitao H, Hirano S, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007;67:7807-7814 (Pubitemid 47281375)
18. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-2706 (Pubitemid 44511633)
19. Janne PA. Challenges of detecting EGFR T790M in gefitinib/ erlotinibresistant tumours. Lung Cancer 2008;60:S3-9.
20. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-7670 (Pubitemid 40741028)
21. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-7101 (Pubitemid 41161238)
22. Ponzetto C, Giordano S, Peverali F, et al. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991;6:553-559 (Pubitemid 21924118)
23. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2008;124:1778-1784
24. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-met. Proc Natl Acad Sci U S A 2008;105:692-697 (Pubitemid 351171770)
25. Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002;8:2273-2285 (Pubitemid 34753601)
26. Herynk MH, Radinsky R. The coordinated functional expression of epidermal growth factor receptor and c-met in colorectal carcinoma metastasis. In Vivo 2000;14:587-596 (Pubitemid 34097519)
27. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31. (Pubitemid 32520251)
28. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-256 (Pubitemid 30781108)
29. Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2008; 63:219-226
30. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15: 2207-2214
31. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-942 (Pubitemid 17027905)
32. Rho JK, Choi YJ, Ryoo BY, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of fas in non-small cell lung cancer. Cancer Res 2007;67:1163-1169 (Pubitemid 46270774)
33. Dona M, Dell' Aica I, Pezzato E, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004;64:6225-6232 (Pubitemid 39129424)